DrugWise Discovery ApS: Financial statements 2023
CVR: 43888862
Source: annual report 2023, Danish Business Authority
16/02/2023 – 31/12/2023
DrugWise Discovery ApS (CVR 43888862) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 286,842 and a net result of DKK 223,041. Equity in the 2023 report amounted to DKK 263,041. The solvency ratio was 72.7%.
- Gross Profit
- DKK 286,842
- Profit/Loss
- DKK 223,041
- Equity
- DKK 263,041
- Total Assets
- DKK 361,939
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of February 16, 2023, Samra Joke Sanni is registered as director of DrugWise Discovery ApS.
As of February 16, 2023, NSSK Holding ApS is registered as an owner of DrugWise Discovery ApS with an ownership share of 100%.
DrugWise Discovery ApS was founded on February 16, 2023.
About DrugWise Discovery ApS
DrugWise Discovery ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2023. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Samra Joke Sanni. The company is owned by NSSK Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 266,857 and a net result of DKK 208,161 compared with DKK 104,809 the year before. Equity in the 2025 report amounted to DKK 575,081.